Amylyx’s ALS Drug Relyvrio Fails In PHOENIX Confirmatory Study, Setting Up Withdrawal Question

 
• By Sue Sutter

Company will meet with regulators and the broader ALS community to discuss top-line results and make ‘informed decisions,’ which may include voluntary withdrawal. During FDA review, Amylyx had pledged to remove Relyvrio if PHOENIX failed.

Light bulbs
The failed PHOENIX study was the confirmatory trial for Relyvrio, which was approved based on the smaller, successful CENTAUR study. • Source: Shutterstock

More from Clinical Trials

More from R&D